echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too

    Yuan Dong, Ted...The siege surged by 300% injections! Osaikon is here too

    • Last Update: 2021-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Recently, Jiangsu Aosaikang Pharmaceutical has entered the administrative examination and approval stage with the imitation of Paricalcitol injection in Category 6 and is expected to be approved in the near future.

    Data show that paricalcitol is the latest generation of selective vitamin D receptor agonists, which can effectively reduce parathyroid hormone (PTH) in combination with vitamin D receptors, and is used to treat chronic renal failure patients undergoing hemodialysis.

    Sales of Paricalcitol Injections in Public Medical Institutions in China in Recent Years

    Source: Terminal competition landscape of China's public medical institutions

    Paricalcitol injection was developed by AbbVie and was approved for marketing by the FDA in 1998.

    Source: MED2.

    In recent years, with the efforts of domestic pharmaceutical companies, AbbVie's paricalcitol injection market share has declined rapidly, from its monopoly in 2017 to less than 20% in the first half of 2020.

    Source: Mi Nei Net database

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.